Sun. Jun 4th, 2023


As time passes, pieces of evidence regarding laboratory origins of SARS-CoV-2 continue to multiply, and this reveals how the leading global institutions placed unfounded and blind trust on a government with controversial methods of rule in front of its own people. Namely, the World Health Organisation and the United Nations decided to ignore calls from doctor whistleblowers in China to research the origins of the virus and to take action to prevent the spread of the virus to other world nations back in January 2020, and the whistleblowers then were “disappeared” by their own government. A major cover-up took place and the Chinese government blamed the onset of the new epidemic on a sudden evolutionary jump of the virus from bats to humans, perhaps via pangolins. This process would be known as zoonosis, and viruses did undergo zoonosis prior to causing epidemic diseases in the human population before. However, the situation with SARS-CoV-2 is much different and highlights the strong signs that this virus did not undergo zoonosis before infecting the first person.

In this report, we will discuss epidemiology and evolutionary biology-related evidence presented recently by the U.S. Senate. Naturally-selected viruses undergo a long process of evolution and zoonosis before reaching a full potential to cause pathogenesis and morbidity in the human organism. The first attack on the human population does not implicate a single outbreak with almost identical viral variants, but several or numerous outbreaks with different variants, which take place overall in years of time before causing the most powerful form of disease. This was not the case with the novel coronavirus, and some may argue that the Chinese government may have covered up prior, smaller outbreaks of this viral disease during the past years, but there would have evidently been clear signs transmitted in the world that that would have been the case.

The last time the novel coronavirus infected an animal (a mammal), in Southern China, before the alleged zoonotic process took place. Source: Dr. John Campbell on YouTube.

Evolutionary studies show that the virus was found in some mammal species in Southern China, close to the border with Thailand, before having been found first in humans, which is shocking news, given that mammals cannot just carry a virus for more than a thousand kilometres and for a number of years before transmitting it to an animal in the Hubei province that would then be killed and placed in a seafood market nearby. Moreover, after an investigation of local search engine history, it was reported that the vast majority of searches of flu-like disease was in an area of Wuhan much closer to the Institute of Virology in Wuhan than to the Huanan Seafood Market.

The number of local search engine clicks on “flu-like disease” collected by the 20th of December 2019. The red dot represents the location of the Huanan Seafood Market and the blue dot represents the location of Institute of Virology in Wuhan, and the outstanding number of online searches came from IP addresses that were located on the same side of the river as the laboratory. Source: Dr. John Campbell on YouTube.

More scientific data was reported on Dr. John Campbell’s report, available at:

The U.S. Senate reported that the laboratory origin scenario is “most likely”. Likewise, if this is the case, then there may really be implications upon the outcome of the mass vaccination campaigns using pathogenic fragments, given that the origins of the virus may have made the spike protein much stronger than it actually was, and that local research-based genetic manipulations, which would most likely be part of gain-of-function research, may bring genetic implications of the spike protein-encoding ribonucleic acid upon the human body, possibly both short- and long-term. Likewise, it would ultimately come to the very institutions that initially assured the world population that the virus came from bats that would bear the burden of guilt, given their persistent refusal not to blindly trust a non-transparent and controversial regime, and to heavily encourage the investigation of the viral origins.

Our question is, why would a scientific paper with concrete studies of bioinformatics for the purpose of genetic analysis and discovery of four outstanding genomic fragments located within the spike protein area with the HIV-1 deadly pathogen, be suddenly retracted? If this would be the case, then there would be an immense negative impact on the developed mRNA vaccines that produce spike proteins. Was it done by free will and true discovery of scientific errors, or was it done under some form of pressure to prevent the flow of such critical information to the public in the name of combatting harmful conspiracy theories? The full text of the retracted paper is available at:

We shall let the audience be the judge.

Reference list:

  1. [Retracted, but important to read] Jiang, H.; Mei, Y.‐F. SARS‐CoV‐2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro. Viruses 2021, 13, 2056. (PDF) SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro. Available from: [accessed Oct 07 2022].
  2. Ives Charlie-Silva, Amanda P. C. Araújo, Abraão T. B. Guimarães, Flávio P Veras, Helyson L. B. Braz, Letícia G. de Pontes, Roberta J. B. Jorge, Marco A. A. Belo, Bianca H, V. Fernandes, Rafael H. Nóbrega, Giovane Galdino, Antônio Condino-Neto, Jorge Galindo-Villegas, Glaucia M. Machado-Santelli, Paulo R. S. Sanches, Rafael M. Rezende, Eduardo M. Cilli, Guilherme Malafaia, An insight into neurotoxic and toxicity of spike fragments SARS-CoV-2 by exposure environment: A threat to aquatic health?, available at: bioRxiv 2021.01.11.425914; doi:
  3. Jafarzadeh, A., Chauhan, P., Saha, B., Jafarzadeh, S., & Nemati, M. (2020). Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions. Life sciences, 257, 118102.
  4. Brown, M., & Bhardwaj, N. (2021). Super(antigen) target for SARS-CoV-2. Nature reviews. Immunology, 21(2), 72.
  5. Huang, Y., Xie, J., Guo, Y., Sun, W., He, Y., Liu, K., Yan, J., Tao, A., & Zhong, N. (2021). SARS-CoV-2: Origin, Intermediate Host and Allergenicity Features and Hypotheses. Healthcare (Basel, Switzerland), 9(9), 1132.
  6. Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings, S.A., Sutherland, A., Premkumar, L., Jadi, R.S., Marrama, D., de Silva, A.M., Frazier, A., Carlin, A.F., Greenbaum, J.A., Peters, B., Krammer, F., Smith, D.M., Crotty, S., & Sette, A. (2020). Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell, 181(7):1489-1501.e15.
  7. Mary Hongying Cheng, She Zhang, Rebecca A. Porritt, Magali Noval Rivas, Lisa Paschold, Edith Willscher, Mascha Binder, Mosche Arditi and Ivet Bahar (2020), Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation, Proceedings of the National Academy of Sciences of the United States of America, 117(41), pp 25254-25262, doi:
  8. Bruttel, V., Washburne, A., & VanDongen, A. (2022). Endonuclease fingerprint indicates a synthetic origin of SARS-COV-2. 
  9. Fleming, D.R.M. (2021). Is COVID-19 a Bioweapon?: A Scientific and Forensic investigation. Skyhorse Publishing (NY). ISBN 978-1-5107-7019-5
  10. Lyons-Weiler, J. (2020). Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoim, 3: 100051.
  11. Navaratnarajah, C. K., Pease, D. R., Halfmann, P. J., Taye, B., Barkhymer, A., Howell, K. G., Charlesworth, J. E., Christensen, T. A., Kawaoka, Y., Cattaneo, R., Schneider, J. W., & Wanek Family Program for HLHS-Stem Cell Pipeline (2021). Highly Efficient SARS-CoV-2 Infection of Human Cardiomyocytes: Spike Protein-Mediated Cell Fusion and Its Inhibition. Journal of virology, 95(24), e0136821.
  12. Buzhdygan, T. P., DeOre, B. J., Baldwin-Leclair, A., Bullock, T. A., McGary, H. M., Khan, J. A., Razmpour, R., Hale, J. F., Galie, P. A., Potula, R., Andrews, A. M., & Ramirez, S. H. (2020). The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. Neurobiology of disease, 146, 105131.
  13. Ken Shirato and Takako Kizaki (2021), SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages, Heliyon 7 e06187, pp 2-9, doi:
  14. Kim, E. S., Jeon, M. T., Kim, K. S., Lee, S., Kim, S., & Kim, D. G. (2021). Spike Proteins of SARS-CoV-2 Induce Pathological Changes in Molecular Delivery and Metabolic Function in the Brain Endothelial Cells. Viruses, 13(10), 2021.
  15. Kalashnyk, O., Lykhmus, O., Izmailov, M., Koval, L., Komisarenko, S., & Skok, M. (2021). SARS-Cov-2 spike protein fragment 674-685 protects mitochondria from releasing cytochrome c in response to apoptogenic influence. Biochemical and biophysical research communications, 561, 14–18.
  16. Segreto, R., & Deigin, Y. (2021). The genetic structure of SARS-CoV-2 does not rule out a laboratory origin: SARS-COV-2 chimeric structure and furin cleavage site might be the result of genetic manipulation. BioEssays : news and reviews in molecular, cellular and developmental biology, 43(3), e2000240.
  17. Singh, P. K., Kulsum, U., Rufai, S. B., Mudliar, S. R., & Singh, S. (2020). Mutations in SARS-CoV-2 Leading to Antigenic Variations in Spike Protein: A Challenge in Vaccine Development. Journal of laboratory physicians, 12(2), 154–160.
  18. Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020). A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature, 584(7821), 353–363.
  19. Ricke D. O. (2021). Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Frontiers in immunology, 12, 640093.
  20. Bournazos, S., Gupta, A., & Ravetch, J. V. (2020). The role of IgG Fc receptors in antibody-dependent enhancement. Nature reviews. Immunology, 20(10), 633–643.
  21. Halstead S. B. (2021). Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 35(5), 505–515.
  22. Bigay, J., Le Grand, R., Martinon, F., & Maisonnasse, P. (2022). Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. Frontiers in microbiology, 13, 932408.
  23. Gartlan, C., Tipton, T., Salguero, F. J., Sattentau, Q., Gorringe, A., & Carroll, M. W. (2022). Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses. Frontiers in immunology, 13, 882972.
  24. Costa Silva, R., Bandeira-Melo, C., Paula Neto, H. A., Vale, A. M., & Travassos, L. H. (2022). COVID-19 diverse outcomes: Aggravated reinfection, type I interferons and antibodies. Medical hypotheses, 167, 110943.
  25. Hu, W. S., & Hughes, S. H. (2012). HIV-1 reverse transcription. Cold Spring Harbor perspectives in medicine, 2(10), a006882.
  26. Desfarges, S., Ciuffi, A. (2012). Viral Integration and Consequences on Host Gene Expression. In: Witzany, G. (eds) Viruses: Essential Agents of Life. Springer, Dordrecht.
  27. Ilaria Sciamanna, Chiara de Luca and Corrado Spadafora (2016), The Reverse Transcriptase Encodes by LINE-1 Retrotransposons in the Genesis, Progression and Therapy of Cancer, Front. Chem., doi:
  28. Zhang L, Richards A, Khalil A, Wogram E, Ma H, Young RA, Jaenisch R. SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome. bioRxiv [Preprint]. 2020 Dec 13:2020.12.12.422516. doi: PMID: 33330870; PMCID: PMC7743078
  29. Tarasova O, Ivanov S, Filimonov DA, Poroikov V. Data and Text Mining Help Identify Key Proteins Involved in the Molecular Mechanisms Shared by SARS-CoV-2 and HIV-1. Molecules. 2020; 25(12):2944.
  30. Doerfler W. (2021). Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome – Are Adenoviral Genes Expressed in Vector-based Vaccines?. Virus research, 302, 198466.
  31. [Retracted, but important to read] Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag Prashant Pradhan, Ashutosh Kumar Pandey, Akhilesh Mishra, Parul Gupta, Praveen Kumar Tripathi, Manoj Balakrishnan Menon, James Gomes, Perumal Vivekanandan, Bishwajit Kundu bioRxiv 2020.01.30.927871; doi:
  32. Kowarz, E., Krutzke, L., Reis, J., Bracharz, S., Kochanek, S., & Marschalek, R. (2021). Vaccine-induced COVID-19 mimicry” syndrome: splice reactions within the SARS-CoV-2 spike open reading frame result in spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines. Nature-portfolio [preprint]
  33. Krutzke, L., Roesler, R., Wiese, S., & Kochanek, S. (2021). Process-related impurities in the ChAdOx1 nCov-19 vaccine. Nature-portfolio [preprint]
  34. NatBiotech, (2016). Research not fit to print. Nat Biotechnol, 34(2): 115. PMID: 26849496
  35. Aldén M, Olofsson Falla F, Yang D, Barghouth M, Luan C, Rasmussen M, De Marinis Y. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. Current Issues in Molecular Biology. 2022; 44(3):1115-1126.
  36. Luisetto, M., Almukthar, N., & Tarro, G., Intracellular Reverse Transcription of COVID-19 mRNA Vaccine, LAP LAMBERT Academic Publishing. 2022; 1, 3-67. ISBN: 978-620-0-31572-4
  37. Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing COVID-19 vaccines at pandemic speed. N Engl J Med, 382:1969-1973;
  38. Kounis, N. G., Koniari, I., Mplani, V., Plotas, P., & Velissaris, D. (2022). Hypersensitivity myocarditis and the pathogenetic conundrum of COVID 19 Vaccine Related Myocarditis. Cardiology, 10.1159/000524224. Advance online publication.
  39. Cadegiani F. A. (2022). Catecholamines Are the Key Trigger of COVID-19 mRNA Vaccine-Induced Myocarditis: A Compelling Hypothesis Supported by Epidemiological, Anatomopathological, Molecular, and Physiological Findings. Cureus, 14(8), e27883.
  40. Hirose, S., Hara, M., Koda, K., Natori, N., Yokota, Y., Ninomiya, S., & Nakajima, H. (2021). Acute autoimmune transverse myelitis following COVID-19 vaccination: A case report. Medicine (Baltimore). 100(51): e28423.
  41. Shao, S.C., Wang, C.H., Chang, K.C., Hung, M.J., Chen, H.Y., & Liao, S.C. (2021). Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerg Infect Dis, 27(12): 3175-3178.
  42. Farinholt, T., Doddapaneni, H., Qin, X., Menon, V., Meng, Q., Metcalf, G., Chao, H., Gingras, M.C., Avadhanula, V., Farinholt, P., Agrawal, C., Muzny, D.M., Piedra, P.A., Gibbs, R.A., & Petrosino, J. (2021) Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections. BMC Med, 19(1): 255.
  43. Goldman, S., Bron, D., Tousseyn, T., Vierasu, I., Dewispelaere, L., Heimann, P., Cogan, E., & Goldman, M. (2021). Rapid progression of angioimmunoblastic T Cell lymphoma following BNT162b2 mRNA vaccine booster shot: a case report. Frontiers in Medicine, 8:798095.
  44. Jureidini J, McHenry L B. The illusion of evidence based medicine BMJ 2022; 376 :o702 doi:10.1136/bmj.o702
  45. Savulescu, J., Giubilini, A., & Danchin, M. (2021). Global Ethical Considerations Regarding Mandatory Vaccination in Children. The Journal of pediatrics, 231, 10–16.
  46. Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. (2021). mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. International journal of pharmaceutics, 601, 120586.
  47. Pardi N., Weissman D. (2017) Nucleoside Modified mRNA Vaccines for Infectious Diseases. In: Kramps T., Elbers K. (eds) RNA Vaccines. Methods in Molecular Biology, vol 1499. Humana Press, New York, NY.
  48. Kirchdoerfer, R. N., Wang, N., Pallesen, J., Wrapp, D., Turner, H. L., Cottrell, C. A., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2018). Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Scientific reports, 8(1), 15701.
  49. Timothy P. Riley, Hui-Ting Chou, Ruozhen Hu, Krzysztof P. Bzymek, Ana R. Correia, Alexander C. Partin, Danqing Li, Danyang Gong, Zhulun Wang, Xinchao Yu, Paolo Manzanillo and Fernando Garces (2021), Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design, Frontiers in Immunology, doi:
  50. Can Li, Yanxia Chen, Yan Zhao, David Christopher Lung, Zhanhong Ye, Wenchen Song, Fei-Fei Liu, Jian-Piao Cai, Wan-Man Wong, Cyril Chik-Yan Yip, Jasper Fuk-Woo Chan, Kelvin Kai-Wang To, Siddharth Sridhar, Ivan Fan-Ngai Hung, Hin Chu, Kin-Hang Kok, Dong-Yan Jin, Anna Jinxia Zhang, Kwok-Yung Yuen, Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model, Clinical Infectious Diseases, 2021;, ciab707,
  51. Gargano, J.W., Wallace, M., Hadler, S.C., Langley, G., Su, J.R., Oster, M.E., Broder, K.R., Gee, J., Weintraub, E., Shimabukuro, T., Scobie, H.M., Moulia, D., Markowitz, L.E., Wharton, M., McNally, V.V., Romero, J.R., Talbot, H.K., Lee, G.M., Daley, M.F., & Oliver, S.E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, MMWR Morb Mortal Wkly Rep, 70(27): 977-982.
  52. Menni, C., Klaser, K., May, A., Polidori, L., Nguzen, L.H., Drew, D.A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L.S., Molteni, E., Graham, M.S., Modat, M., Joshi, A.D., Mangino, M., Hammers, A., Goodman, A.L., Chan, A.T., Wolf, J., Steves, C.J., Valdes, A.M., Ourselin, S., & Spector, T.D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis, 21(7): 939-949.
  53. Block, J. (2021). Vaccinating people who have had covid-19: why doesn’t natural immunity count in the US?. BMJ, n2101. doi: 10.1136/bmj.n2101
  54. Jiang, S. (2020). Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature, 579: 321.
  55. Kostoff, R.N., Calina, D., Kanduc, D., Briggs, M.B., Vlachoyiannopoulos, P., Svistunov, A.A., & Tsatsakis, A. (2021). Why are we vaccinating children against COVID-19? Toxicol Rep. 8: 1665-1684.
  56. Cabanillas, B., Akdis, C., & Novak, N. (2021). Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?. Allergy, 76(6), 1617-1618. doi: 10.1111/all.14711
  57. Kim, M.A., Lee, Y.W., Kim, S.R., Kim, J.H., Min, T.K., Park, H.S., Shin, M., Ye, Y.M., Lee, S., Lee, J., Choi, J.H., Jang, G.C., & Chang, Y.S. (2021). COVID-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group. Allergy Asthma Immunol Res, 13(4):526-544.
  58. Cerpa-Cruz, S., Paredes-Casillas, P., Landeros Navarro, E. et al. Adverse events following immunization with vaccines containing adjuvants. Immunol Res 56, 299–303 (2013).
  59. Sangaletti, P., Doe, J., Gatti, A., Arvay, C., Giuliani, L., & Lettner, H. (2022). SARS-CoV-2 and the Vaccination Hype. International Journal of Vaccine Theory, Practice, and Research, 2(1), 173–207. (Original work published January 18, 2022)
  60. Sumi, T., Nagahisa, Y., Matsuura, K., Sekikawa, M., Yamada, Y., Nakata, H., & Chiba, H. (2021). Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer-BioNTech). Thorac Cancer, 12: 3072-3075.
  61. Shimoyama, S., Kanisawa, Y., Ono, K., Souri, M., & Ichinose, A. (2021). First and fatal case of autoimmune acquired factor XIII/13 deficiency after COVID-19/SARS-CoV-2 vaccination. Am J Hematol, 1–3.
  62. Seneff, S., Nigh, G. (2021). Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. International Journal of Vaccine Theory, Practice, and Research, 2(1): 38-79. Retrieved from
  63. Uriu, K., Kimura, I., Shirakawa, K., Takaori-Kondo, A., Nakada, T.A., Kaneda, A., The Genotype to Phenotype Japan (G2P-Japan) Consortium, Nakagawa, S., & Sato, K. (2021). Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera. bioRxiv, 2021.09.06.459005.
  64. Inserra, F., Tajer, C., Antonietti, L., Mariani, J., Ferder, L., & Manucha, W. (2021). Vitamin D supplementation: An alternative to enhance the effectiveness of vaccines against SARS-CoV-2? Vaccine, 39(35): 4930-4931.
  65. Grenfell, B.T., Pybus, O.G., Gog, J.R., Wood, J.L., Daly, J.M., Mumford, J.A., & Holmes, E.C. (2004). Unifying the epidemiological and evolutionary dynamics of pathogens. Science, 303(5656): 327-332.
  66. Villarreal, L.P. (2015) Virolution Can Help Us Understand the Origin of Life. In: Kolb V (ed). Astrobiology – An Evolutionary Approach. CRC Press, Boca Raton (FL); ISBN 13-978-1-4665-8462-4
  67. Villarreal, L.P., Witzany, G. (2021) Social networking of quasi-species consortia drive virolution via persistence. AIMS Microbiology, 7(2): 138-162.
  68. Ho, M.-W. (2013). The new genetics and natural versus artificial genetic modification. Entropy, 15(11), 4748–4781.
  69. Ho, M.-W. (1999). Genetic Engineering, Dream or Nightmare? The Brave New World of Bad Science and Big Business, 2nd ed. Gateway Books, Dublin (IRL). ISBN 0-8264-1257-2
  70. Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, C., & Ortiz-Ospina, E. (2021). A global database of COVID-19 vaccinations. Nat Hum Behav 5: 947-953. doi: 10.1038/s41562-021-01122-8; Data on COVID-19 (coronavirus) vaccinations by Our World in Data, accessible:
  71. Cerezo, L., & Macià I Garau, M. (2012). Acute radiation syndrome and Fukushima: A watershed moment?. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 17(1), 1–3.
  72. Rios, C. I., Cassatt, D. R., Hollingsworth, B. A., Satyamitra, M. M., Tadesse, Y. S., Taliaferro, L. P., Winters, T. A., & DiCarlo, A. L. (2021). Commonalities Between COVID-19 and Radiation Injury. Radiation research, 195(1), 1–24.

Featured image: By Ureem2805 – Own work, CC BY-SA 4.0,

By Anonymous Graduate

A graduate from a Science-related University Bachelor's, discussing public health corruption and half-truths promoted abundantly in mainstream Academia.

3 thoughts on “Shocking evidence of SARS-CoV-2 genetic manipulation”

Leave a Reply

Your email address will not be published. Required fields are marked *